Journey Medical Co. (NASDAQ:DERM) CEO Sells $122,006.52 in Stock

Journey Medical Co. (NASDAQ:DERM) CEO Claude Maraoui sold 23,508 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $5.19, for a total transaction of $122,006.52. Following the completion of the sale, the chief executive officer now owns 2,139,922 shares in the company, valued at approximately $11,106,195.18. This trade represents a 1.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Claude Maraoui also recently made the following trade(s):

• On Wednesday, March 5th, Claude Maraoui sold 18,147 shares of Journey Medical stock. The stock was sold at an average price of $5.13, for a total transaction of $93,094.11.

Journey Medical Stock Performance

Shares of NASDAQ:DERM opened at $5.23 on Thursday. The company has a market capitalization of $109.25 million, a price-to-earnings ratio of -5.56 and a beta of 0.96. Journey Medical Co. has a 12 month low of $2.85 and a 12 month high of $6.89. The firm’s 50-day moving average is $4.54 and its 200 day moving average is $5.07. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81.

Hedge Funds Weigh In On Journey Medical

Several hedge funds have recently added to or reduced their stakes in the company. Tang Capital Management LLC bought a new position in Journey Medical during the 4th quarter valued at about $6,747,000. PVG Asset Management Corp grew its holdings in Journey Medical by 5.7% during the 3rd quarter. PVG Asset Management Corp now owns 167,545 shares of the company’s stock valued at $947,000 after purchasing an additional 9,005 shares during the last quarter. Geode Capital Management LLC grew its holdings in Journey Medical by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock valued at $613,000 after purchasing an additional 12,882 shares during the last quarter. Citadel Advisors LLC bought a new position in Journey Medical during the 4th quarter valued at about $174,000. Finally, Kovitz Investment Group Partners LLC grew its holdings in Journey Medical by 112.9% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company’s stock valued at $97,000 after purchasing an additional 13,105 shares during the last quarter. 7.25% of the stock is currently owned by institutional investors.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.